Method of treating vegetovascular dystonia and pharmaceutical composition for treating vegetovascular dystonia

FIELD: medicine, pharmaceutics.

SUBSTANCE: present group of inventions refers to medicine, namely to therapy, and concerns treating vegetovascular dystonia (VVD). That is ensured by administering a pharmaceutical composition containing activated potentiated angiotensin II receptor antibodies and activated potentiated endothelial NO-synthase antibodies.

EFFECT: method provides effective treatment of vegetovascular dystonia ensured by the synergetic action of the ingredients of the pharmaceutical composition.

1 ex, 1 tbl

 

The invention relates to medicine and can be used for effective treatment of vegetative-vascular dystonia (VVD).

The prior art known drug for the treatment of hypertension, on the basis of activated forms of ultra-low doses of antibodies to receptor of angiotensin II (Use of ultra-low doses of antibodies to C-terminal fragment AT1receptor of angiotensin II (cardos valleys) in the treatment of hypertension. Nedogoda SV, I. Epstein 2006). However, this drug does not provide a sufficient therapeutic efficacy in the treatment of various disorders in the body when IRR.

The invention is aimed at establishing an effective and comprehensive preparation in the form of pharmaceutical compositions and improving the treatment of dystonia.

The solution of this problem is provided by the fact that in the method for the treatment of dystonia, by introducing into the body of a medicinal product on the basis of the activated - potentiated form of ultra-low doses of affinity purified antibodies to the receptor of angiotensin II, prepared by multiple consecutive breeding and external influences, according to the invention, optionally simultaneously and co-injected activated - potentiated form of ultra-low doses of affinity purified antibodies to endothelial NO-synthase is.

Using the activated - potentiated form of antibodies to C-terminal fragment AT! - receptor of angiotensin II and the activated - potentiated form of antibodies to endothelial NO-synthase.

In addition, the activated - potentiated form of antibodies to C-terminal fragment AT1-receptor of angiotensin II and the activated - potentiated form of antibodies to endothelial NO-synthase is used in the form of activated - potentiated aqueous or aqueous-alcoholic solution of each component, obtained in the process of consecutive multiple-dilution in water or water-alcohol solvent and an intermediate external mechanical impact - vertical shaking.

Used cooked as a single drug - single dosage form a mixture of homeopathic dilutions of antibodies to C-terminal fragment AT1-receptor of angiotensin II in combination with a mixture of homeopathic dilutions of antibodies to endothelial NO-synthase.

Perhaps the use of the pharmaceutical composition on the basis of the activated - potentiated form of ultra-low doses of affinity purified antibodies to the C-terminal fragment AT1-receptor of angiotensin II and to endothelial NO-synthase in combination with known standard drugs is nami means, used for the treatment of diseases of the cardiovascular system of the following groups: ACE inhibitors including in combination, diuretics, β-blockers, nitrates, cardiac glycosides, cholesterol-lowering means, antiplatelet agents, antihypoxants, anticoagulants.

The solution of this problem is provided by the fact that drug for the treatment of dystonia based on the activated - potentiated form of ultra-low doses of affinity purified antibodies to the receptor of angiotensin II, according to the invention, made in the form of a pharmaceutical composition and further comprises as a reinforcing component of the activated - potentiated form of antibodies to endothelial NO-synthase.

When this activated - potentiated form of antibodies to receptor of angiotensin II and to endothelial NO-synthase is used in the form of activated - potentiated aqueous or aqueous-alcoholic solution obtained in the process of consecutive multiple-dilution matrix solution of the corresponding antibodies in aqueous or aqueous-alcoholic solvent and an intermediate external mechanical impact - vertical shaking.

In addition, the pharmaceutical composition can be made in solid dosage form and contain an effective amount neutralinos the media, saturated with a mixture of activated - potentiated form of antibodies to receptor of angiotensin II and an activated - potentiated form of antibodies to endothelial NO-synthase, and pharmaceutically acceptable additives, which may include lactose, cellulose microcrystalline and magnesium stearate.

When this aqueous or aqueous-alcoholic solutions of the activated - potentiated form of antibodies to receptor of angiotensin II and to endothelial NO-synthase obtained by repeated consecutive dilution and intermediate external influence from the matrix solutions of affinity purified antibodies to the receptor of angiotensin II and to endothelial NO-synthase with a concentration of 0.5÷5.0 mg/ml

Moreover, each of the components of ultra-low doses of affinity purified antibodies are used in the form of a mixture of various, mainly centesimal homeopathic dilutions.

In addition, the pharmaceutical composition contains : active ingredients: activated - potentiated form of antibodies to C-terminal fragment AT1receptor of angiotensin II and to endothelial NO-synthase in the ratio of 1:1, with each component used in ultra-low dose in the form of a mixture of three corresponding matrix solutions, diluted in 10012, 10030and the 100200once that is equivalent to boast of homeopathic dilutions C12, C30, C200.

<> Perhaps the claimed pharmaceutical composition on the basis of activated forms of ultra-low doses of affinity purified antibodies to disease C-terminal fragment AT1-receptor of angiotensin II and to endothelial NO-synthase also be used in combination with known standard drugs used for the treatment of diseases of the cardiovascular system of the following groups:

- ACE inhibitors including combined (Enap, enalapril, capoten, Renitec, Prestarium (berlipril, Diroton, capoten, quadrupel, monopril, Renitec, Prestarium, noliprel-Forte, Enap-H));

- diuretics (furosemide, verospiron, gipotiazid, arifona retard, indapamide, gipotiazid, diver, indap, indapamide);

- β-blockers (egilok, atenolol, Concor, betaloc ZOK);

- nitrates (dilucida, kardiket, kardiket-record, metrolina, Monomac, monocycle, nitroglycerin, nitrosorbid, Ricard, petrol, sinopharm);

- cardiac glycosides (digoxin);

- calcium antagonists (normodipina, cordaflex, allows, amlodipine, allows, Amlotop, cardilopin, cordaflex, cordipin PI);

- lipid-lowering means (vasilip, Liprimar, liponorm, simwagexal, simvasta, simvacard, simgal, Tulip)

antiplatelet agents (aspirin, cardiac, cardiomagnyl, trombas);

- antihypoxants (Preductal MB, Preductal, trimetal);

- anticoagulants (who arfarin).

The claimed pharmaceutical composition is recommended, preferably, 1-2 tablets 2-4 times a day.

In the treatment the treatment of dystonia may separate application in the form of two separately prepared drugs in the form of solutions and in solid dosage forms (tablets), each of which contains activated - potentiated form of ultra-low doses of affinity purified antibodies to disease C-terminal fragment AT1-receptor of angiotensin II and, accordingly, the activated-potentiated form of ultra-low doses of affinity purified antibodies to endothelial NO-synthase

The proposed pharmaceutical composition based on the activated - potentiated form of ultra-low doses of affinity purified antibodies to disease C-terminal fragment AT1-receptor of angiotensin II and to endothelial NO-synthase (i.e. forms antibodies to C-terminal fragment AT1-receptor of angiotensin II and to endothelial NO-synthase, prepared according to homeopathic technology exponentiation by repeated consecutive dilution and intermediate external effects - vertical shaking, which has activity in pharmacological models and/or clinical treatment methods dystonia) provides obtaining neojidannogo the synergistic therapeutic effect, confirmed experimentally, which is normalizerbase action on the autonomic status in patients with vascular dystonia and fatigue, anti-anxiety and antidepressant activity.

In this application of the claimed pharmaceutical compositions for the treatment of patients with diseases of the cardiovascular system leads to improved quality of life, particularly in patients improve the quality of life, assessed according to the criteria of depression, anxiety, duration of the walk, the increased tolerance to physical load, etc.

In addition, the claimed technical solution expands the Arsenal of drugs for the treatment IRR.

The pharmaceutical composition is prepared mainly as follows.

For making an activated - potentiated form of active components, using monoclonal or, mostly, polyclonal antibodies, which can be obtained by known technologies - techniques are described, for example, in the book: Immunological methods, Ed. by Grimes, M, "Medicine", 1987, p.9-33; or, for example, article Laffly E., R. Sodoyer Hum. Antibodies. Monoclonal and recombinant antibodies, 30 years after. - 2005 - Vol.14. - N 1-2. P.33-55.

Monoclonal antibodies receive, for example, using hibriDomna technology. Moreover, the initial stage of the PR, the process includes immunization, based on the principles already developed in the preparation of polyclonal antisera. Further stages include obtaining hybrid cells that produce clones of the same specificity of antibodies. Their separation into individual form is carried out in the same manner as in the case of polyclonal antisera.

Polyclonal antibodies can be obtained by active immunization of animals. For this purpose a specially designed circuit animals make a series of injections required in accordance with the invention substance - antigen: endothelial NO-synthase and C-terminal fragment AT1receptor of angiotensin II. As a result of this procedure is to get the monospecific anticigarette with a high content of antibodies, which is used to produce the activated potentiated form. If necessary, conduct the purification of antibody present in anticigarette, for example, by the method of affinity chromatography, by application of salt fractionation by precipitation or ion exchange chromatography.

Preferred for the preparation of the claimed pharmaceutical compositions is the use of polyclonal antibodies to endothelial NO-synthase and C-terminal fragment AT1receptor of angiotensin II, which as a matrix (primary) solution with what concentratie of 0.5÷5.0 mg/ml, used for the subsequent preparation of the activated - potentiated form.

Preferred for the preparation of each component is the use of a mixture of three aqueous-alcohol dilutions of the initial matrix solution of antibodies, diluted, respectively, in the 10012, 10030and the 100200time, which corresponds to boast of homeopathic dilutions C12, C30 and C200. In carrying out the stated drugs in solid dosage form on the lactose is applied a mixture of these components.

Preferred for the preparation of the claimed medicinal preparation is the use of polyclonal antibodies to the C-terminal fragment AT1receptor of angiotensin II and endothelial NO-synthase, which can be obtained by immunization of rabbits as follows.

To obtain polyclonal antibodies to C-terminal fragment AT1the angiotensin II receptor as an immunogen (antigen) for immunization of rabbits using adjuvant and C-terminal fragment AT1receptor of angiotensin II select, for example, from the following groups:

GKKFK RYFLQLLKYI PPKAKSHSNL STKMSTLSYR PSDNVSSSTK KPAPCFEVE

LNPF FYVFFGKNFK KYFLQLIKYI PPNVSTHPSL TTKMSSLSYR

PPENIRLPTK

KTAGSFDTE

QLLKYI RRCA

SSLSYR PPENIR

QLIKYIPPNVSTHP

SNL STKMSTLSYR PSDNVSSSTK KPAPCF

It is possible to obtain polyclonal antibodies to C-terminal fragment AT receptor of angiotensin II using as immunogen (antigen) C - terminal fragment of the receptor AT1 angiotensin II person added to the N end of a Cysteine (C):

CGKKF KRYFL QLLKY IPPKA KSHSN LSTKM STLSY RPSDN VSSST CCRR CFEVE

Before taking the blood sample for 7-9 days spend 1-3 intravenous injection for raising antibodies. In the process of immunization in rabbits take small blood samples to estimate the number of antibodies. The maximum level of immune response to the introduction of most soluble antigens is achieved in 40-60 days after the first injection. After completion of the first cycle immunization of rabbits for 30 days to give to restore health and are reimmunization including 1-3 intravenous injection. To obtain antisera from immunized rabbits collect the blood in a centrifuge tube with a volume of 50 ml using a wooden spatula to remove from the walls of the tube formed clots and put the wand in the clot formed in the center of the tube. The blood is placed in a refrigerator (4°C) overnight. The next day remove the clot adhered to the spatula, and centrifuged remaining liquid at 13,000 g for 10 min. the Supernatant (supernatant) is anticorodal. The resulting anticavity should be yellow. Add to anticigarette 20% (weight concentration) NaN to a final concentration of 0.02% and stored until use in a frozen state at -20°C. For allocation from the antisera antibody to the C-terminal fragment AT1receptor of angiotensin II to produce absorption in the solid phase in the following sequence:

1. 10 ml of rabbit antisera diluted 2 times with 0.15 M NaCl type of 6.26 g of Na2SO4, mixed and incubated for 12-16 h at 4°C;

2. the precipitation is removed by centrifugation, dissolved in 10 ml of phosphate buffer and then cialiswhat against the same buffer overnight at room temperature;

3. after removal of the precipitate by centrifugation, the solution was applied to the column with DEAE-cellulose, equilibrated with phosphate buffer;

4. the fraction of antibodies determined by measuring the optical density of the eluate at 280 nm.

Then make a clearance antibodies by the method of affinity chromatography obtained by attaching antibodies to the C-terminal fragment AT1receptor of angiotensin II, which is insoluble matrix followed by elution with concentrated salt solutions.

Obtained, thus, the buffer solution polyclonal rabbit antibodies against the C-terminal fragment AT1receptor of angiotensin II, purified on antigen, with a concentration of 0.5÷5.0 mg/ml, preferably. 2,0÷3,0 mg/ml, used as Matri is the main (primary) solution for the subsequent preparation of the activated - potentiated form.

Polyclonal antibodies to endothelial NO-synthase get similar to the above method, using as immunogen (antigen) for immunization of rabbits with adjuvant whole molecule endothelial NO-synthase following sequence:

1 MGNLKSVGQE PGPPCGLGLG LGLGLCGKQG PASPAPEPSR ARARATYAN DHSPAPNSPT

61 LTRPPEGPKF PRVKNWELGS ITYDTLCAQS QQDGPCTPRR CLGSLVLPRK LQTRPSPGPP

121 PAEQLLSQAR DFINQYYSSI KRSGSQAHEE RLQEVEAEVA STGTIHLRES ELVFGAKQAW

181 RNAPRCVGRI QWGKLQVFDA RDCSSAQEMF TYICNHIKYA TNRGNLRSAI TVFPQRAPGR

241 GDFRIWNSQL VRYAGYRQQD GSVRGDPANV EITELCIQHG WTPGNGRFDV LPLLLQAPDE

301 APELFVLPPE LVLEVPLGAP HTGVVRGPGL RWYALPAVSN MLLEIGGLEF SAAPFSGWYM

361 STEIGTRNLC DPHRYNILED VAVCMDLDTR TTSSLWKDKA AVEINLAVLH SFQLAKVTIV

421 DHHAATVSFM KHLDNEQKAR GGCPADWAWI VPPIYGSLPP VFHQEMVNYI LSPAFRYQPD

481 PWKGSATKGA GITRKKTFKE VANAVKISAS LMGTLMAKRV KATILYASET GRAQSYAQQL

541 GRLFRKAFDP RVLCMDEYDV VSLEHEALVL VVTSTFGNGD PPENGESFAA ALMEMSGPYN

601 SSPRPEQHKS YKIRFNSVSC SDPLVSSWRR KRKESSNTDS AGALGTLRFC VFGLGSRAYP

661 HFCAFARAVD TRLEELGGER LLQLGQGDEL CGQEEAFRGW AKAAFQASCE TFCVGEEAKA

721 AAQDIFSPKR SWKRQRYRLS AQAEGLQLLP GLIHVHRRKM FQATVLSVEN LQSSKSTRAT

781 ILVRLDTAGQ EGLQYQPGDHIGISAPNRPG LVEALLSRVE DPPPPTESVA VEQLEKGSPG

841 GPPPSWVRDP RLPPCTVRQA LTFFLDITSP PSPRLLRLLS TLAEEPSEQQ ELETLSQDPR

901 RYEEWKLVRC PTLLEVLEQF PSVALPAPLL LTQLPLLQPR YYSVSSAPNA HPGEVHLTVA

961 VLAYRTQDGL GPLHYGVCST WLSQLKTGDP VPCFIRGAPS FRLPPDPYVP CILVGPGTGI

1021 APFRGFWQER LHDIESKGLQ PHPMTLVFGC RCSQLDHLYR DEVQDAQERG VFGRVLTAFS

1081 REPDSPKTYV QDILRTELAA EVHRVLCLER GHMFVCGDVT MATSVLQTVQ RILATEGDME

1141 LDEAGDVIGV LRDQQRYHED IFGLTLRTQE VTSRIRTQSF SLQERHLRGA VPWAFDPPGP

1201 DTPGP

It is possible to obtain polyclonal antibodies to endothelial NO-synthase using as immunogen (antigen) of whole molecules of endothelial NO-with whom ntasy the following sequence:

1 MGNLKSVAQE PGPPCGLGLG LGLGLCGKQG PATPAPEPSR APASLLPPAP EHSPPSSPLT

61 QPPEGPKFPR VKNWEVGSIT YDTLSAQAQQ DGPCTPRRCL GSLVFPRKLQ GRPSPGPPAP

121 EQLLSQARDFINQYYSSIKR SGSQAHEQRL QEVEAEVAAT GTYQLRESEL VFGAKQAWRN

181 APRCVGRIQW GKLQVFDARD CRSAQEMFTY ICNHIKYATN RGNLRSAITV FPQRCPGRGD

241 FRIWNSQLVR YAGYRQQDGS VRGDPANVEI TELCIQHGWT PGNGRFDVLP LLLQAPDDPP

301 ELFLLPPELV LEVPLEHPTL EWFAALGLRW YALPAVSNML LEIGGLEFPA APFSGWYMST

361 EIGTRNLCDP HRYNILEDVA VCMDLDTRTT SSLWKDKAAV EINVAVLHSY QLAKVTIVDH

421 HAATASFMKH LENEQKARGG CPADWAWIVP PISGSLTPVF HQEMVNYFLS PAFRYQPDPW

481 KGSAAKGTGI TRKKTFKEVA NAVKISASLM GTVMAKRVKA TILYGSETGR AQSYAQQLGR

541 LFRKAFDPRV LCMDEYDVVS LEHETLWLVV TSTFGNGDPP ENGESFAAAL MEMSGPYNSS

601 PRPEQHKSYK IRFNSISCSD PLVSSWRRKR KESSNTDSAG ALGTLRFCVF GLGSRAYPHF

661 CAFARAVDTR LEELGGERLL QLGQGDELCG QEEAFRGWAQ AAFQAACETF CVGEDAKAAA

721 RDIFSPKRSW KRQRYRLSAQ AEGLQLLPGL IHVHRRKMFQ ATIRSVENLQ SSKSTRATIL

781 VRLDTGGQEG LQYQPGDHIG VCPPNRPGLV EALLSRVEDP PAPTEPVAVE QLEKGSPGGP

841 PPGWVRDPRL PPCTLRQALT FFLDITSPPS PQLLRLLSTL AEEPREQQEL EALSQDPRRY

901 EEWKWFRCPT LLEVLEQFPS VALPAPLLLT QLPLLQPRYY SVSSAPSTHP GEIHLTVAVL

961 AYRTQDGLGP LHYGVCSTWL SQLKPGDPVP CFIRGAPSFR LPPDPSLPCI LVGPGTGIAP

1021 FRGFWQERLH DIESKGLQPT PMTLVFGCRC SQLDHLYRDE VQNAQQRGVF GRVLTAFSRE

1081 PDNPKTYVQD ILRTELAAEV HRVLCLERGH MFVCGDVTMA TNVLQTVQRI LATEGDMELD

1141 EAGDVIGVLR DQQRYHEDIF GLTLRTQEVT SRIRTQSFSL QERQLRGAVP WAFEPPGSDT

1201 NSP

It is possible to obtain polyclonal antibodies to endothelial NO-synthase using as immunogen (antigen) a synthetic peptide of endothelial NO-synthase, selected, for example, of the following amino acid sequences:

1192-1195

PWAF

1189-1192:

RGAVP

1185-1205

RHLRGAVPWAF DPPGPDTPGP

1194-1205:

AF DPPGPDTPGP

1186-1196:

HLRGAVPWAF D

1186-1205:

HLRGAVPWAF DPPGPDTPGP

The activated - potentiated form of each of the components is prepared by the uniform decrease of the concentration in the serial dilutions 1 of the above matrix solution of 9 parts (for decimal dilution) or 99 parts (for centesimal dilution) or in 999 parts (for the thousandth breeding) neutral solvent with multiple vertical shaking ("dynamics") of each received cultivation and use separate containers for each subsequent breeding until you get the desired potency - ratio cultivation in homeopathic method (see, for example, Usabe "Homeopathic medicinal product", M, 1967, p.14-29).

For example, for the preparation of the 12th centesimal dilution C12 one part of the mentioned matrix solution of antibodies to C-terminal fragment AT1receptor of angiotensin II with a concentration of 3.0 mg/ml diluted in 99 parts of a neutral aqueous or aqueous-alcoholic solvent (mostly 70% ethyl alcohol) and repeatedly (10 times or more) vertically shaken - potentiate received 1st somenoe C1 breeding. From the 1st centesimal C1 breeding prepare 2nd somenoe breeding C2. This operation is repeated 11 times, getting 12th somenoe breeding C12. Thus, 12th somenoe breeding C12 represents the solution obtained by diluting consistently in different tanks 12 times the 1st part of the initial matrix solution of antibodies to C-terminal fragment AT1receptor of angiotensin II with a concentration of 3.0 mg/ml in 99 parts of a neutral solvent, i.e., the solution prepared from the matrix solution, otvedennogo 100 times, equivalent SITENAME homeopathic dilution C12. Similar operations with a corresponding multiplicity of cultivation is performed to obtain a dilution C30 and C200.

When used as a biologically active liquid component of the mixture of different homeopathic, mainly centesimal, dilutions, the active substance each component of the composition (for example, C12, C30, C200) prepare separately for the above-described technology to their penultimate cultivation (respectively, to obtain C11, C29, C199) and then applied in accordance with the composition of the mixture in one container, one part of each component and mixed with the required amount of solvent (respectively, with 97 parts for centesimal dilution). You get the activated - potentiated form of antibodies to C-terminal fragment AT1receptor of angiotensin II in ultra-low dose of each component prepared from a matrix solution and diluted to 10012in the 10030100200that is equivalent to a mixture of centesimal homeopathic dilutions C12, C30 and C200.

You can use the active substance in the form of a mixture of various other homeopathic, dilutions, for example, the decimal or centesimal, (D20, C30, C100 or C12, SO, C50, etc.), the effectiveness of which is determined experimentally.

When potentiation instead of shaking in p is acesse reduce the concentration can also be external exposure to ultrasound, electromagnetic or other physical impact

To obtain the claimed pharmaceutical compositions are aqueous or aqueous-alcoholic solutions of the active components are mixed, predominantly, in the ratio of 1:1 and used in liquid dosage form. Preferably the pharmaceutical composition comprises an activated - potentiated form of antibodies to C-terminal; the fragment AT1receptor of angiotensin II and to endothelial NO-synthase in ultra-low dose of each component in ultra-low dose of each component prepared from a matrix solution and diluted to 10012in the 10030100200that is equivalent to a mixture of centesimal homeopathic dilutions C12, C30 and C200.

The claimed pharmaceutical composition can be used in solid dosage form that contains an effective amount of granules neutral media - lactose, saturated by soaking up the saturation a mixture of aqueous or aqueous-alcoholic solutions of the activated - potentiated form of antibodies to C - terminal fragment AT1receptor of angiotensin II and the activated - potentiated form of antibodies to endothelial NO-synthase, and pharmaceutically acceptable additives, including, primarily, lactose, cellulose microcrystalline and magnesium stearate.

To obtain solid oral the second form of the claimed medicinal product produced in the plant fluidized bed (e.g., type "Huttlin Pilotlab" production company Huttlin GmbH) irrigation until saturation of injected fluid - fluidized bed granules of neutral matter - of lactose (milk sugar) with a particle size of 150÷300 μm, a pre-obtained aqueous or aqueous-alcoholic solution of activated - potentiated forms of antibodies to C-terminal fragment AT1receptor of angiotensin II and endothelial synthase nitric oxide (NO-synthase), mainly in the ratio of 1 kg of the solution of antibodies to 5 or 10 kg of lactose (1:5-1:10) with simultaneous drying in a stream supplied under the grate of heated air at a temperature not exceeding 40°C. the Estimated number 0,17÷0,34 by weight of the solid oral form) dried granules, saturated activated - potentiated form of antibodies, are loaded into the mixer and mixed with microcrystalline cellulose, enter the number 3÷8 mass. parts by weight of the total load from the mass of solid oral forms. Then to this mixture 25÷45 mass. parts by weight of the total load "unsaturated" pure lactose (to reduce the cost and some simplification and acceleration of the process without reducing the effectiveness of therapeutic effects), magnesium stearate in an amount of 0.1÷0.3 mass. parts by weight of the total load and microcrystalline cellulose in an amount of 3÷8 mass. parts by weight of the total load. Receiving the ing tablets weight evenly mixed and tabletirujut direct dry pressing (for example, in tablet press Korsch-XL400) with the formation of round tablets weighing 150÷500 mg. After tabletting get a tablet weight of 300 mg, impregnated with a water-alcohol solution (3,0-6,0 mg/tab.) the activated - potentiated form of antibodies to C-terminal fragment AT1receptor of angiotensin II and NO-synthase in midget doses, each component prepared from a matrix solution and diluted to 10012in the 10030100200that is equivalent to a mixture of centesimal homeopathic dilutions C12, C30 and C200.

Preferably the claimed pharmaceutical composition is recommended to take 1-2 tablets 2-4 times a day.

For the experimental studies were used antibodies, cooked to order specialized pharmaceutical company.

Example 1.

Clinical efficacy and safety of the pharmaceutical composition on the basis of the component of activated - potentiated forms of antibodies in ultra-low doses (ULD) to the C-terminal fragment AT1receptor of angiotensin II and to endothelial NO-synthase (mixture of homeopathic dilutions C12, C30, C200) investigated 60 patients of both sexes (male - to 26.7% (n=16), women 73,3% (n=44) of the total number of patients with fatigue (more than 12 points under the item "General fatigue" on the subjective scale fatigue MFI-20 (Multidimensional Fatigue Inventory)and weget the vascular dystonia (more than 15 points on the scale vegetation changes in age from 29 to 64 years (average of 47.1±1,77 years) in a double-blind placebo-controlled randomized clinical trial in parallel groups.

Patients were randomized into two groups (n=30 in each). Patients of the 1st group received claimed the drug per 1 tablet 3 times a day. Patients in group 2 received placebo 1 tablet 3 times a day. The total duration of the drug and monitor the patients was 6 months.

The treatment efficacy was assessed by the dynamics of indicators of subjective rating scale fatigue, questionnaires to assess levels of anxiety and depression (scale of spielberger and Beck), questionnaires assessing sleep questionnaire vegetative changes.

The dynamics of changes in autonomic and psychological status, quality of life of patients on the background of therapy are presented in table 1.

It is shown that application claimed the drug for 6 months resulted in a statistically significant decrease in the level of fatigue in all podskalan MFI-20. Most improved significantly following indicators: General fatigue (from 12.9±0,21 to 10.9±0,27 points, p<0,01 from the placebo group), physical fatigue (from 12.3±0,56 to 10.2±0.39 points, p<0,05 from the placebo group), mental fatigue (from 10.2±0,47 to 8.9±0.41 points, p<0,05 from the placebo group). After 1 month of treatment in the main group 1 there was a statistically significant decrease in the severity of autonomic changes (according to the specialized questionnaire), after 6 months of treatment achieved result is you (reduction in total score from 28.9±1,66 to 17.6±0,76) statistically significantly (p< of 0.05) differed from the performance of the group placebo (reduction in total score from 32.1±3,36 to 22.4±2,08).

Also the use of the claimed drug contributed to the improvement of psychological status of the patients. A statistically significant reduction in anxiety and depression was observed already after 1 month of therapy, during the continuation of positive change was growing. At the completion of 6 months in group 1 the level of reactive anxiety on a scale of spielberger (reduced from 39.3±1,02 to 32,4±0.76 points) and level of depression by questionnaire Beck (decrease from 9.2±0,44 to 7.8±0.31 points) is statistically significant. (p<0.05)and differed from the corresponding values of the placebo group (decreased from 42.7±2.65 to 37,6±1,81 and 11.1±1,43 to 9.9±0.90 points, respectively). The results were confirmed by positive dynamics (p<0,001 from the original values) indicators questionnaire on sleep, after 6 months of treatment total score in group 1 (increase from 16.9±0,44 to 19.4±0,29) was statistically significantly (p<0,05) higher than in the placebo group (an increase of 16.6±0,67 to 18.2±0,47).

During the whole period of observation of the patients showed good tolerability, adverse events were absent.;,

Thus, the conducted research showed that the pharmaceutical composition on the basis of antibodies to C-terminal fragment of the AT1 receptor for angiotensin I (a mixture of homeopathic dilutions C12+C30+C200) and of ULD of antibodies to endothelial NO-synthase (mixture of homeopathic dilutions C12+C30+C200) has antiasteniceski action has a normalizing effect on the autonomic status in patients with vascular dystonia and fatigue, has anti-anxiety and antidepressant activity.

Table 1.
IndexCombined drug, n=30Placebo, n=30
Visit 1Visit 2 (4 weeks)Visit 3 (12 weeks)Visit 4 (24 weeks)Visit 1Visit 2 (4 weeks)Visit 3 (12 weeks)Visit 4 (24 weeks)
General fatigue scale (MFI-20)M±M12,9±0,2112,3±0,2911,5±0,35*** #10,9±0,27*** ##13,1±0,2612,9±0,2312,5±0,17***11,9±0,19***
Physical fatigue scale (MFI-20)M±M12,3±0,5611,7±0,49** 11,2±0,45**10,2±0,39*** #12,3±0,3812,1±0,2911,7±0,29 **11,4±0,21**
Reduced activity scale (MFI-20)M±M10,3±0,5010,1±0,479,5±0,42*9,1±0,28*10,6±0,6310,1±0,53*9,7±0,50**9,5±0,38**
Decrease motivation scale (MFI-20)M±Ma 9.60±0,559,5±0,478,6±0,32*8,3±0,27*9,9±0,759,7±0,579,4±0,519,3±0,48
Mental fatigue scale (MFI-20)M±M10,20±0,479,7±0,44*9,5±0,42*8,9±0,41** #10,8±0,5110,6±0,4310,5±0,4010,3±0,38
The questionnaire vegetative changed the th (total point) M±M28,9±1,6625,3±1,26**22,1±1,26***17,6±0,76*** #32,1±3,3629,5±2.57 m)*25,9±2,42***22,4±2,08***
Questionnaire evaluation of sleep (total point)M±M16,9±0,4418,4±0,42**18,9±0,34***19,4±0,29*** #16,6±0,6717,5±0,56**18,1±0,47***18,2±0,47 ***
Personal anxiety (scale of spielberger)M±M37,6±2,0335,6±1,42*35,1±1,64**32,9±1,23***39,1±3,0538,7±2,7836,9±2,45*36,9±2,46*
Reactive anxiety (selectively)M±M39,3±1,0235,7±0,72*** #34,5±1,02***32,4±0,76*** #2,7±2,65 40,3±1,99**38,3±1,87**37,6±1,81**
The Beck depression inventory (total point)M±M9,2±0,448,4±0,25*8,3±0,27*7,8±0,31** #11,1±1,4310,5±1,19*10,0±0,939,9±0,90*
The significance of differences compared to the original indicator: * p<0,05, ** p<0,01, *** p<0,001. The significance of differences compared with the placebo group: * p<0,05, ## p<0,01, ### p<0,001.

1. The method of treatment vegetalis diet composition by introducing into the body of a medicinal product on the basis of the activated-potentiated form affinity purified antibodies to the receptor of angiotensin II, prepared by multiple consecutive breeding and external influences, characterized in that additionally at the same time and co-injected activated - potentiated form affinity purified antibodies to endothelial NO-synthase.

2. The method according to claim 1, characterized in that use activated - potentiated form of antibodies to C - terminal fragment AT1- receptor angiome the Zina II and the activated-potentiated form of antibodies to endothelial NO - the synthase.

3. The method according to claim 1 or claim 2, characterized in that the activated - potentiated form of antibodies to C - terminal fragment AT1- receptor of angiotensin II and the activated-potentiated form of antibodies to endothelial NO-synthase is used in the form of activated - potentiated aqueous or aqueous-alcoholic solution of each component, obtained in the process of consecutive multiple-dilution in water or water-alcohol solvent and an intermediate external mechanical impact - shaking of every dilution.

4. The method of treatment according to claim 1 or claim 2, characterized by the fact that the use of the pharmaceutical composition prepared in the form of a single drug - single dosage form, which includes a mixture of different homeopathic dilution of antibodies to C - terminal fragment AT1- receptor of angiotensin II in combination with a mixture of different homeopathic dilution of antibodies to endothelial NO-synthase.

5. The method of treatment according to claim 1 or claim 2, characterized by the fact that the use of the pharmaceutical composition on the basis of the activated-potentiated form affinity purified antibodies to C - terminal fragment AT1- receptor of angiotensin II and endothelial N0 - synthase in combination with known standard drugs is, used for the treatment of diseases of the cardiovascular system of the following groups: ACE inhibitors including in combination, diuretics, (3-blockers, nitrates, cardiac glycosides, calcium antagonists, lipid-lowering means, antiplatelet agents, antihypoxants, anticoagulants.

6. Drug for treatment vegetalis diet composition according to claim 1 on the basis of the activated - potentiated form affinity purified antibodies to the receptor of angiotensin II, which is characterized by the fact that made in the form of a pharmaceutical composition and further comprises as a reinforcing component of the activated - potentiated form of antibodies to endothelial NO-synthase.

7. The drug according to claim 6, characterized in that the activated - potentiated form of antibodies to receptor of angiotensin II and to endothelial NO-synthase is used in the form of activated - potentiated aqueous or aqueous-alcoholic solution obtained in the process of consecutive multiple-dilution matrix solution of the corresponding antibodies in aqueous or aqueous-alcoholic solvent and an intermediate external mechanical impact - shaking of every dilution.

8. The drug according to claim 6 or claim 7, characterized in that the pharmaceutical composition is made in solid cure the Noi form and contains an effective amount of saturated activated - potentiated form of antibodies to receptor of angiotensin II and an activated - potentiated form of antibodies to endothelial NO-synthase granules neutral carrier and pharmaceutically acceptable additives.

9. The drug according to claim 6 or claim 7, characterized in that an aqueous or aqueous-alcoholic solutions of the activated - potentiated form of antibodies to receptor of angiotensin II and to endothelial NO-synthase obtained by repeated consecutive dilution and intermediate external influence from the matrix solutions of affinity purified antibodies to the receptor of angiotensin II and to endothelial NO-synthase with a concentration of 0.5÷5.0 mg/ml

10. The drug according to claim 6 or claim 7, characterized in that each of the components of the affinity purified antibodies are used in the form of a mixture of various, mainly centesimal homeopathic dilution.

11. The drug of claim 8, characterized in that the pharmaceutically acceptable additives include lactose, cellulose microcrystalline and magnesium stearate.



 

Same patents:

FIELD: biotechnology.

SUBSTANCE: invention relates to binuclear form of dinitrosyl iron complex with ethyl ether of glutathione (DNIC-EEG) of the formula [(EEGS)2Fe2(NO)4] with the structural formula: , where R-S represents ethyl ether of glutathione containing a thiol group. The invention also relates to a composition for reducing functional disorders of myocardium subjected to hypoxia-reoxygenation which contains binuclear form of dinitrosyl iron complex with ethyl ether of glutathione (DNIC EEG) as defined above and a pharmaceutically acceptable carrier. Also the use of DNIC-EEG is disclosed as antihypoxic agent.

EFFECT: reduction of hypoxic contracture, arrhythmias intensity and improvement of recovery of contractile function of the heart after reoxygenation.

3 cl, 1 tbl, 16 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula , wherein A means a six-merous aryl radical or a five-merous heteroaryl radical which contains one heteroatom specified in oxygen and sulphur; one or more hydrogen atoms in the above aryl or heteroaryl radicals can be substituted by substituting groups R1 which are independently specified in a group consisting of: F, Cl, Br, I, (C1-C10)-alkyl-, (C1-C10)-alkoxy-, -NR13R14; B means a radical with mono- or condensed bicyclic rings specified in a group consisting of: six-ten-merous aryl radicals, five-ten-merous heteroaryl radicals and nine-fourteen-merous cycloheteroalkylaryl radicals, wherein cycloheteroalkyl links can be saturated or partially unsaturated, while the heterocyclic groups can contain one or more heteroatoms specified in a group consisting of nitrogen, oxygen and sulphur, one or more hydrogen atoms in the radical groups B can be substituted by substituting groups R5 (as specified in the patent claim), L means a covalent bond, X means the group -O-, R2 is absent or means one or more substitutes specified in F and (C1-C4)-alkyl radical; R3 and R4 independently mean (C1-C10)-alkyl, (C3-C14)-cycloalkyl, (C4-C20)-cycloalkylalkyl, (C2-C19)-cycloheteroalkyl, (C3-C19)-cycloheteroalkylalkyl, (C6-C10)-aryl, (C7-C20)-arylalkyl, (C1-C9)-heteroaryl, (C2-C19)-heteroarylalkyl radicals, or R3 and R4 together with nitrogen attached whereto can form a four-ten-merous saturated, unsaturated or partially unsaturated heterocyclic compound which can additionally contain one or more heteroatoms among -O-, -S(O)n-, =N- and -NR8-; other radicals are such as specified in the patient claim. Also, the invention refers to using the compound of formula I for preparing a drug.

EFFECT: compounds of formula (I) as Na+/H+ metabolism inhibitors NHE3.

22 cl, 27 dwg, 1 tbl, 756 ex

FIELD: medicine.

SUBSTANCE: method involves preliminary intraperitoneal single administration of 5% aqueous alloxan in a dose of 15 mg/kg of body weight into a rat's body on an empty stomach. That is followed by administering afobazol under conditions of oxidative stress after observing the rat's blood glucose gain at least twice. Afobazol is administered subcutaneously in a dose of 10 mg/kg of body weight once a day for 30 days with underlying administration of L-arginine in a dose of 10 mg/kg of body weight or with underlying NG-nitroarginine methyl ester (L-NAME)-inhibitor of NOS-3 enzyme in a dose of 25 mg/kg of animal's weight.

EFFECT: method enables correcting the oxidative stress and NO-producing endothelial dysfunction accompanying vascular complications of diabetes mellitus.

1 dwg, 6 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: kit of apiphytoagents containing: 'Bee active Tentorium' pills, 'Khlebina' pills, 'Apiphytotonus' apicomposition, 'Assile-concentrate' aqueous solution, 'Apihit' oily solution, 'APV' aqueous solution, 'Tentorium Cream' cream for external application, for non-medicinal prevention of a cardiovascular risk and increase of the capacity in junior and young sportsmen. A method for non-medicinal prevention of the cardiovascular risk and increase of the capacity in junior and young sportsmen consisting in administering apiphytoproducts in certain regimens.

EFFECT: kit is effective for non-medicinal prevention of the cardiovascular risk and increase of the capacity in junior and young sportsmen.

2 cl, 16 dwg, 9 tbl

FIELD: medicine.

SUBSTANCE: complex of biologically active substances for treating and preventing cardiovascular diseases, recovered from sea urchin gonads Strongylocentrotus droebachiensis free from ballast substances, prepared by extraction of the purified gonads in 95% ethanol under certain conditions, separation of a dry ethanolic extract and drying. An agent for treating and preventing cardiovascular diseases containing the complex of biologically active substances.

EFFECT: complex and agent are effective in treating and preventing cardiovascular diseases.

4 cl, 1 dwg, 4 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and deals with a composition for treating cardiac tissue, containing TGFβ-1, BMP4, α-thrombin, cardiotrophin and cardiogenol C, a method of obtaining differentiated cells-cardioprecursors from mammalian stem cells, including cultivation of initial cells in presence of the said composition; a method of providing cardiac tissue with cardiomyocytes, which includes introduction of differentiated cells, obtained by the method of obtaining described above, into cardiac tissue.

EFFECT: group of inventions ensures an improved specificity in a regulation of transcription of genes, required for differentiation induction.

27 cl, 23 dwg, 1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and concerns methods of treating growth hormone or insulin-like growth factor 1 deficiency in a patient involving administering an immunogenic amount of a vaccine containing a chimeric somatostatin-14 based polypeptide bound to inactivated chloramphenicol acetyltransferase (CAT), and an adjuvant; the vaccine for treating the patient having growth hormone or insulin-like growth factor 1 deficiency; a method of treating obesity in the patient involving administering the immunogenic amount of the vaccine.

EFFECT: group of inventions provide the immunogenicity for somatostatin and higher release of endogenously produced growth hormone and/or insulin-like growth factor 1.

22 cl, 8 ex, 6 dwg, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a crystalline salt of (1R*,2R*,4R*)-2-(2-{[3-(4,7-dimethoxy-1H-benzoimidazol-2-yl)propyl]methylamino}ethyl)-5-phenylbicyclo[2.2.2]oct-5-en-2-yl isobutyric acid ester. Also, the invention refers to a pharmaceutical composition of the above crystalline salt and using the above crystalline salt for preparing the pharmaceutical composition.

EFFECT: what is prepared is the crystalline salt of (1R*,2R*,4R*)-2-(2-{[3-(4,7-dimethoxy-1H-benzoimidazol-2-yl)propyl]methylamino}ethyl)-5-phenylbicyclo[2,2,2]oct-5-en-2-yl isobutyric acid ester that can be effective as a L/T-type calcium channel blocker.

15 cl, 11 dwg, 10 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: claimed invention relates to field of organic chemistry, namely to novel compound of formula (I), where Y and Z, each independently, are selected from group, consisting of: a) phenyl, if necessary substituted with 1 or 2 R6; b) pyridine, imidazole, thiazole, furan, triazole, quinoline or imidazopyridine, if necessary substituted with 1 R6; and c) substituent, independently selected from group, consisting of hydrogen, C1-C6alkyl or pyperidine; R1, R2 and R3, each independently selected from group, consisting of hydrogen and halogen; A and B is each independently selected from hydrogen, OH and C1-C6alkyl; RA and RB are independently selected from group, consisting of hydrogen, C1-C6alkyl and C3-C8cycloalkyl; or RA and RB together with atom, to which they are attached, form 4-6-membered heterocycle, if necessary having additionally one heteroatom or functional heterogrpoup, selected from group, consisting of -O-, -NH, -N(C1-C6-alkyl)- and -NCO(C1-C6-alkyl)-, and 6-membered heterocycle can be additionally substituted with one or two C1-C6-alkyl groups; R4 and R5, each stands for hydrogen; and each R6 is selected from Br, Cl, F, I, C1-C6-alkyl, pyrrolidine, if necessary substituted with one C1-C6-alkyl, C1-C6alkoxy, halogen-C1-C6alkyl, hydroxyl-C1-C6alkylene, -(NRARB)C1-C6alkylene and (NRARB)carbonyl; or to its individual isomer, stereoisomer or enantiomer, or their mixture, if necessary pharmaceutically acceptable salt. Invention also relates to compound of formula (II), particular compounds of formula (I) and (II), pharmaceutical composition and industrial product based on compound of formula (I) and (II), method of treating said pathological conditions, method of obtaining formula (I) compound and to intermediate compound of formula 3.

EFFECT: novel compounds, useful as inhibitors of poly(ADP-ribose)polymerase, are obtained.

50 cl, 1 tbl, 159 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to spiro-5,6-dihydro-4H-2,3,5,10b-tetra-aza-benzo[e]azulene derivatives of formula I, where X-Y represents C(RaRb)-O, where each of Ra and Rb independently represents H or C1-4-alkyl, C(RcRd)-S(O)p, where each of Rc and Rd independently represents H, C(O)O, CH2OCH2, CH2CH2O, Z represents CH or N; R1 represents halogeno, R2 represents H, C1-6-alkyl, non-substituted or having as substituents one OH, -(CH2)q-Re, where Re represents pyridyl, -C(O)-C1-6-alkyl, -C(O)(CH2)qNRiRii, -C(O)O-C1-6-alkyl, -S(O)2NRiRii, each of Ri and Rii independently represents C1-6-alkyl, R3 represents Cl or F, n has value 1 or 2, m has value 0, 1, p has value 0 or 2, q has value 1, or to their pharmaceutically acceptable salts. Invention also relates to pharmaceutical composition, possessing antagonistic activity with respect to receptors V1a, on the basis of said compounds.

EFFECT: obtained are novel compounds and pharmaceutical composition on their basis, which can be applied in medicine as drugs of peripheral and central action in case of the following states: dysmenorrhea, male or female sexual disfunction, hypertension, chronic heart failure, inadequate secretion of vasopressin, liver cirrhosis, nephritic syndrome, anxiety, depressive disorders, obsessive-compulsive disorder, autism spectrum disorders, schizophrenia and aggressive behaviour.

20 cl, 10 tbl, 37 ex

FIELD: medicine.

SUBSTANCE: conduit wall is presented by a material of random micro- and nanofibres of a bioresorptive polymer of poly(ε-caprolactone), and the content is presented by a self-assembled nanostructured hydrogel of acetyl-(Arg-Ala-Asp-Ala)4-CONH2(PuraMatrix™) oligopeptide. The above conduit is implanted in a complex with the direct local delivery of vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2) genes to be introduced into the proximal and distal nerve segments, while the formed conduit is implanted into a nerve rupture, and its ends are fixed with epineural sutures.

EFFECT: invention provides a stimulating effect on the invasion of regenerative medullated fibres, on the recovery of motor and sensitive nerve function, and enables improving the effect of the recovery of the nerve structure and function after the extended ruptures.

4 cl

FIELD: medicine.

SUBSTANCE: osteosynthesis of long bones is followed by the hydropreparation through a Dufaut's needle; 0.9% sodium chloride 2 ml is introduced above an epineural space; epidural and epineural electrodes assisted by an electromyography and an electronic image converter are implanted and sutured on the skin. The postoperative period involves a complex course of the electrical stimulation through the epidural and epineural electrodes in a combination with a superficial cutaneous electrical stimulation of independent regions for 15-20 days.

EFFECT: method enables reducing the injuries accompanying the electrode placement and improving the motor activity of the extremities by the complex electrical stimulation.

2 dwg, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely - to neurology. The method involves the integrated treatment. Azathioprine, dexamethasone and analgin are administered into the patient. Azathioprine 50 mg is administered three times a day, after meals for 21 days. Dexamethasone 4 mg is administered intramuscularly three times a day for 15 days. From the 16th to 18th day of treatment, dexamethasone 4 mg is administered 2 times a day - in the morning and afternoon. From the 19th to 20th day, the same is administered in a dose of 4 mg in the afternoon. Before bedtime, 50% analgin 2.0 ml is administered parenterally for 10 days. At 9 o'clock in the morning, patient's lumbar pain area is exposed to the magnetic laser treatment. The patient is exposed to infrared light of wave length 0.8-0.9 mcm, pulse power 5-8 Wt, pulse frequency 1000 Hz and magnetic strength 35 mT. The exposure is contact and stable, and covers the fields paravertebrally. The length of the one-field exposure is 2 minutes. The therapeutic course is 15 procedures. Trives spinal assistant is put on in the horizontal position of lying on back. The spinal assistant is taken off in the horizontal position before bedtime.

EFFECT: method reduces the length of treatment, prolongs a remission, including due to the developed modes and combinations of the various components of the exposure.

1 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to therapy and neurology, and concerns using fatty acid/fatty acids Omega-3 as a part of an analgesic drug. That is ensured by administering an analgesic and/or preventative drug that contains the above acid/acids in the free or bound agent in the amount of more than 2 g. The administration is single oral or intravenous.

EFFECT: administering Omega-3 fatty acid/fatty acids in the above doses provides the analgesic effect regardless of causes of the pain.

10 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely neurology, physiotherapy. The solution of proserine is introduced 30 minutes before conducting low intensity electrical stimulation. Amplitude of the electrical stimulation is 10-20 mA, frequency is 40-40 Hz, and length is 900 seconds.

EFFECT: method reduces the length of treatment, raises muscle tone, desensitizes the peripheral innervation region.

3 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to reconstructive surgery of peripheral nerves, and can be applied for substitution of peripheral nerve defects in case of their posttraumatic injury. Method includes intersection of neuromas and substitution of defect with autonervous insertions. Sampling of autologous fat tissue from patient is preliminarily realised by method of liposuction. Cells of stromal vascular fraction (SVF) are obtained from it after carrying out enzymatic processing. Obtained SVF cells are intraneurally transplanted into peripheral and central nerve segments, and into each insertion. Ends of nerve, as well as insertions, are covered with fibrin adhesive.

EFFECT: in conditions of clinical practice method makes it possible to restore functions of injured nerve with considerable reduction of treatment terms.

1 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is using the material for the purpose of neural dysfunction recovery with the above material containing a polysaccharide derivative hydrogel wherein 0.5 wt % of the aqueous solution contains a complex module in the amount of 1 to 1000 N/m2, while a loss factor makes 0.01 to 2.0 that is measured at angular velocity 10 rad/sec with using a dynamic viscoelasticity meter. The above material for neural dysfunction recovery may represent hydrogel injected with using a syringe and has an excellent body residence, and has a restorative effect on the damaged or degenerated nerve function.

EFFECT: preparing the material for neural dysfunction recovery.

19 cl, 6 dwg, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to neurology, neurosurgery and rehabilitation, and may be used to recover the sensor-motor function of the central nervous system and peripheral nerves. The therapy is three-staged. At the first stage, at least two hollow electrodes made of biologically neutral conductive material in a proximal and distal direction from a nerve injury are implanted into the nerve. The second stage involves at least one course of a focused extracorporeal shock-wave therapy consisting in at least five sessions in a combination with intraneural electric stimulation and intraneural ionic medication aiming at stimulating the growth of peripheral nerve fibre axons and the regeneration of Schwann cells forming the medullary sheath. At the third stage, the implanted electrodes are removed, and at least one session of transcutaneous electric stimulation with one-step electric myoneurography is conducted to coordinate neural pulses passage through the newly formed peripheral nerve synapses.

EFFECT: method provides the high therapeutic effectiveness in case of injuring up to 90% of neural synapses, reduced length of rehabilitation up to the complete recovery in the patient with no contra-indications and a possibility of the outpatient care.

6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics, namely a method for preparing and purifying monosialoganglioside GM1. The method for preparing pure monosialoganglioside GM1 in the form of its sodium salt involves (a) GM1 separation from Fucosyl GM1 in a lipid mixture containing monosialoganglioside GM1 as a main ganglioside component by a column ion-exchange chromatography using an eluent comprising potassium or cesium ions, (b) recovery of the dissolved substance from the eluted solution, (c) diafiltration of the aqueous solution of the recovered dissolved substance of the stage (b), (d) addition of sodium salt, and diafiltration of the prepared aqueous solution (d) recovery of GM1 in the form of its sodium salt. The method for purifying monosialoganglioside GM1 from Fucosyl GM1 in the lipid mixture, the column ion-exchange chromatography using the eluent comprising potassium or cesium ions. The preparation of monosialoganglioside GM1 has a purity of 99.0% or more, and contains less than 0.1% of Fucosyl GM1. The method of treating disorders and diseases of the central nervous system and the peripheral nervous system, comprising administering the preparation of monosialoganglioside GM1 to the patient in its effective amount. The use of the preparation of monosialoganglioside GM1 in preparing a pharmaceutical composition.

EFFECT: use the above preparation of monosialoganglioside GM1 in treating has the considerable advantages due to reducing side effects.

17 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pediatric neurology, and can be used for rehabilitation of neurological disorders in children in case of neuroinfections. For this purpose, at the background of adequate complex and pathogenetic therapy, parenteral introduction of actovegin in acute period of disease additionally from the first days of disease cytoflavin is introduced intravenously by drop infusion in dose 0.6 ml/kg or 10 ml per day for 3-5 days, elcar perorally in dose 70-100 mg/kg of weight per day for 3-4 weeks. In the period of early reconvalescence pantogam is additionally introduced perorally in dose 50-70 mg/kg of weight per day for 4 weeks. In case if multifocal affection of brain substance is present, gliatilin is introduced intravenously by drop infusion in dose 1 ml per 5 kg of body weight per day in combination with intramuscular introduction of ipidacrine in dose 5-15 mg per day for 7-10 days, after that gliatilin perorally in dose 50 mg/kg of weight per day together with ipidacrine inside in dose 1 mg/kg per day for 4 weeks.

EFFECT: method makes it possible to improve disease outcome due to reduction of frequency of residual neurological deficiency formation with reduction of term of hospital treatment.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to medicine, specifically cardiology, and concerns treating chronic cardiac failure. That is ensured by administering a pharmaceutical composition containing an activated potentiated form of very-low-dose angiotensin II receptor antibodies and an activated potentiated form of very-low-dose endothelial NO-synthase antibodies.

EFFECT: method provides improving quality of life and higher tolerance to physical loads in the given group of patients.

11 cl, 2 ex, 2 tbl

Up!